Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Sterling Pharma and Seqens boost pharma service R&D
by Rick Mullin
April 7, 2022
| A version of this story appeared in
Volume 100, Issue 12
Sterling Pharma Solutions plans to invest $1.3 million to expand R&D at a drug services site in Deeside, Wales, dedicated to bioconjugation and antibody-drug conjugates. The project will increase laboratory space by about 50% and create room for further expansion. Meanwhile, Seqens plans a “multi-million-dollar” R&D investment at its drug services facility in Devens, Massachusetts. Seqens was acquired by SK Capital Partners last year.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X